Core Viewpoint - The company reported a decline in revenue and net profit for the third quarter of 2025 compared to the previous year, indicating potential challenges in its financial performance [1] Financial Performance - In the third quarter of 2025, the company achieved an operating income of 115 million yuan, a year-on-year decrease of 6.54% [1] - The net profit attributable to shareholders was 5.7694 million yuan, with a basic earnings per share of 0.01 yuan [1] - For the first three quarters of 2025, the company reported an operating income of 351 million yuan, down 2.44% year-on-year [1] - The net profit attributable to shareholders for the first three quarters was 27.6322 million yuan, with a basic earnings per share of 0.07 yuan [1]

Core Viewpoint - On October 27, a total of 10 listed companies had their restricted shares unlocked, with a total market value of approximately 18.54 billion yuan [1] Summary by Category Restricted Share Unlocking - Xiamen Bank (601187) extended the lock-up period for 1.348 billion shares [1] - Guangzheng Eye Hospital (002524) released 2.2245 million shares under equity incentive restrictions [1] - Shapuaisi (603168) released 30,000 shares under equity incentive restrictions [1] - Yifeng Pharmacy (603939) released 195,000 shares under equity incentive restrictions [1] - Jihong Co., Ltd. (002803) released 1.98 million shares under equity incentive restrictions [1] - Mingyang Circuit (300739) released 1.2387 million shares under equity incentive restrictions [1] - Arrow Home (001322) released 800 million shares under pre-issue restrictions [1] - Ruichen Environmental Protection (301273) released 3.70125 million shares under pre-issue restrictions [1] - Jinchengzi (688291) released 6.9 million shares [1] - Weice Technology (688372) released 2.70328 million shares [1]

Core Viewpoint - The company, Shapais, announced the completion of the first subject enrollment in the Phase III clinical trial for its drug, Litasite Eye Drops [2] Group 1 - The company organized the Phase III clinical trial for Litasite Eye Drops [2] - The announcement was made on the evening of October 24 [2] - The trial has successfully enrolled its first participant [2]

Core Viewpoint - The company Shapuaisi (603168.SH) has received the drug registration certificate for Oubukain Hydrochloride Eye Drops from the National Medical Products Administration, indicating a significant advancement in its product offerings in the ophthalmology field [1] Group 1 - The approved Oubukain Hydrochloride Eye Drops are intended for surface anesthesia in ophthalmology [1]

Core Viewpoint - The company has completed the enrollment of the first subject in the Phase III clinical trial for Latanoprost eye drops, aimed at evaluating its efficacy and safety in treating dry eye in the Chinese population [1] Group 1 - The Phase III clinical trial is designed as a multi-center, randomized, double-blind, placebo-controlled study [1] - The trial's primary focus is to assess the effectiveness and safety of Latanoprost eye drops in the treatment of dry eye [1] - The first subject was enrolled on October 23, 2025 [1]

Core Viewpoint - The company, Shapuaisi (603168.SH), has received the drug registration certificate for Oubukain Hydrochloride Eye Drops from the National Medical Products Administration, indicating a significant advancement in its product offerings in the ophthalmology field [1] Group 1 - The approved Oubukain Hydrochloride Eye Drops are intended for surface anesthesia in ophthalmology [1]

药品批准文号：国药准字H20255752 证券代码：603168 证券简称：莎普爱思 公告编号：临 2025-059 浙江莎普爱思药业股份有限公司 关于获得盐酸奥布卡因滴眼液 《药品注册证书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，浙江莎普爱思药业股份有限公司（以下简称"公司"、"莎普爱思"）收到 国家药品监督管理局核发的盐酸奥布卡因滴眼液的《药品注册证书》（证书编号： 2025S03202），现将有关信息公告如下： 一、《药品注册证书》主要内容 药品名称：盐酸奥布卡因滴眼液 剂型：眼用制剂 规格：0.4%（0.5ml：2mg） 注册分类：化学药品4类 上市许可持有人：浙江莎普爱思药业股份有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药 品注册的有关要求，批准注册，发给药品注册证书。 二、药品其他情况 本次获批的盐酸奥布卡因滴眼液，可用于眼科领域内的表面麻醉。 截至本公告披露日，公司针对该药品的累计研发投入约为 372.64 万元人民币。 三、对公司的影响、后续安排及风险 ...

证券代码：603168 证券简称：莎普爱思 公告编号：临 2025-060 剂型：眼用制剂 注册分类：化学药品3类 二、立他司特滴眼液临床试验相关情况 立他司特滴眼液Ⅲ期临床试验，采用多中心、随机、双盲、安慰剂平行对照 设计，评价立他司特滴眼液在中国人群中治疗干眼的有效性和安全性，已于2025 年10月23日完成首例受试者入组。 截至本公告披露日，立他司特滴眼液项目累计研发投入约1,915.15万元人民 币。 浙江莎普爱思药业股份有限公司 关于立他司特滴眼液 III 期临床试验 完成首例受试者入组的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，浙江莎普爱思药业股份有限公司（以下简称"公司"）组织开展的立 他司特滴眼液III期临床试验完成首例受试者入组。具体情况如下： 一、立他司特滴眼液基本情况 药品名称：立他司特滴眼液 三、风险提示 根据中国药品注册相关的法律法规要求，药物在获得临床试验批准后，须完 成临床试验方可进行药品注册上市许可申请。 由于药物研发的特殊性，药物从临床试验到投产的周期长，环节多，易受不 可预 ...

Core Viewpoint - The company has initiated a Phase III clinical trial for its drug, Litasan Eye Drops, aimed at treating dry eye in the Chinese population, with the first subject enrolled on October 23, 2025 [1] Group 1: Clinical Trial Details - The trial is designed as a multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of the drug in the target population [1] - As of the announcement date, the total research and development investment for this project has reached approximately 19.15 million yuan [1] Group 2: Development Risks - The drug development process from clinical trials to production is lengthy and involves multiple stages, which may lead to potential issues that could result in the termination of the research [1] - The company commits to providing timely updates on the progress of the trial [1]

Core Viewpoint - The company received the drug registration certificate for Oubkain Hydrochloride Eye Drops from the National Medical Products Administration, indicating a significant regulatory approval for a product used in ophthalmic surface anesthesia [1] Company Summary - Shapais (603168) announced on October 24 that it has obtained the drug registration certificate for Oubkain Hydrochloride Eye Drops [1] - The eye drops are intended for use in the field of ophthalmology, specifically for surface anesthesia [1]